GSK Acquires Exclusive Rights for Antibody Drug Conjugate
GSK plc and Syndivia, a private biotechnology company, have announced an agreement granting GSK exclusive worldwide rights to develop and commercialize a preclinical ADC for metastatic castration-resistant prostate cancer (mCRPC).
Approximately 1.4 million men worldwide are diagnosed with prostate cancer each year, with 10-20% developing advanced disease within five years.
For patients with mCRPC, targeted treatment options are limited, and standard of care options may be difficult to access and poorly tolerated, with modest efficacy outcomes.
Survival rates for these patients are low, with a 5-year survival rate of approximately 30% and a median survival of approximately two years.
No specific quote available in the given text.
Author's summary: GSK acquires exclusive rights for prostate cancer treatment.